More than 13,500 people contracted COVID-19 in Connecticut between Aug. 1 and Oct. 5, according to the most recent state data ...

New Data to be Presented at IDWeek 2024 Reinforce Merck’s Broad and Diverse Vaccines and Infectious Disease Pipeline and ...

Molnupiravir, an antiviral drug used to treat patients with COVID-19, appears to be driving SARS-CoV-2 to mutate and evolve, with some of these new viruses being transmitted onwards, a new study ...

Molnupiravir speeds up recovery and eases long-term symptoms, but its minimal effect on hospitalizations raises questions about its broader impact on COVID-19 care. Study: Health outcomes 3 months ...

Today, Wedgewood announces the addition of molnupiravir to its formulary. Originally developed for human viral infections, including COVID-19, molnupiravir has emerged as a promising option for ...

SWEDESBORO, N.J., September 18, 2024--(BUSINESS WIRE)--Today, Wedgewood announces the addition of molnupiravir to its formulary. Originally developed for human viral infections, including COVID-19 ...

SWEDESBORO, N.J., September 18, 2024--(BUSINESS WIRE)--Today, Wedgewood announces the addition of molnupiravir to its formulary. Originally developed for human viral infections, including COVID-19, ...

New research has found that molnupiravir offers modest longer term benefits to vaccinated adults. This is the latest outcome of the NIHR funded and delivered PANORAMIC trial, led by the University of ...

SWEDESBORO, N.J.--(BUSINESS WIRE)--Today, Wedgewood announces the addition of molnupiravir to its formulary. Originally developed for human viral infections, including COVID-19, molnupiravir has ...

People with acute COVID-19 who took the antiviral drug molnupiravir (Lagevrio) reported modest improvements in symptoms, less ...

A new COVID variant, XEC, has arrived just before fall. The new variant has sprouted from the Omicron variant that developed ...

At last count, the 9.7% of people taking placebo in the trial had become seriously will with COVID-19, compared to 6.8% of the molnupiravir group. Fall in efficacy of Merck's molnupiravir puts ...